JP2017528431A5 - - Google Patents

Download PDF

Info

Publication number
JP2017528431A5
JP2017528431A5 JP2017502821A JP2017502821A JP2017528431A5 JP 2017528431 A5 JP2017528431 A5 JP 2017528431A5 JP 2017502821 A JP2017502821 A JP 2017502821A JP 2017502821 A JP2017502821 A JP 2017502821A JP 2017528431 A5 JP2017528431 A5 JP 2017528431A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
composition
active
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017502821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528431A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/040879 external-priority patent/WO2016011335A1/en
Publication of JP2017528431A publication Critical patent/JP2017528431A/ja
Publication of JP2017528431A5 publication Critical patent/JP2017528431A5/ja
Pending legal-status Critical Current

Links

JP2017502821A 2014-07-17 2015-07-17 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム Pending JP2017528431A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462025714P 2014-07-17 2014-07-17
US62/025,714 2014-07-17
PCT/US2015/040879 WO2016011335A1 (en) 2014-07-17 2015-07-17 Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Publications (2)

Publication Number Publication Date
JP2017528431A JP2017528431A (ja) 2017-09-28
JP2017528431A5 true JP2017528431A5 (2) 2018-08-16

Family

ID=55079079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017502821A Pending JP2017528431A (ja) 2014-07-17 2015-07-17 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム

Country Status (9)

Country Link
US (1) US20170173060A1 (2)
EP (1) EP3169331A4 (2)
JP (1) JP2017528431A (2)
KR (1) KR20170026635A (2)
CN (1) CN106687119A (2)
AU (1) AU2015289511A1 (2)
CA (1) CA2955425A1 (2)
IL (1) IL250170A0 (2)
WO (1) WO2016011335A1 (2)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8999721B2 (en) 2009-10-23 2015-04-07 Therabrake, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
US20180099001A1 (en) 2011-04-29 2018-04-12 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
CN108697768B (zh) 2015-12-23 2022-07-22 约翰霍普金斯大学 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
US10398389B1 (en) 2016-04-11 2019-09-03 Pricewaterhousecoopers Llp System and method for physiological health simulation
WO2017203367A2 (en) * 2016-05-22 2017-11-30 Volant Holdings Gmbh Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
CA3052975A1 (en) 2017-02-10 2018-08-16 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating disease associated with permeability of intestinal epithelium
WO2018204918A1 (en) * 2017-05-05 2018-11-08 Ardelyx, Inc. Treatment of hepatic disorders
CN111094537A (zh) * 2017-09-08 2020-05-01 自然免疫制御技术研究组合 阿尔茨海默症诊断装置及方法
CA3087953C (en) * 2018-01-12 2025-11-25 Metimedi Pharmaceuticals Co., Ltd. METHODS OF TREATMENT FOR CHRONIC INFLAMMATORY DISEASES
KR102282490B1 (ko) * 2018-01-12 2021-07-28 주식회사 엠디헬스케어 패칼리박테리움 프라우스니찌 유래 나노소포 및 이의 용도
KR20200128407A (ko) * 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
CA3092930A1 (en) * 2018-03-07 2019-09-12 Anabio Technologies Ltd. A composition for type ii diabetics and for use in providing sustained energy release over time
WO2020081369A1 (en) * 2018-10-15 2020-04-23 James Glenn Norman Applied artificial intelligence technology for hormone therapy treatment
US10803981B2 (en) 2018-10-15 2020-10-13 James Glenn Norman Applied artificial intelligence technology for hormone therapy treatment
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
WO2021069504A1 (en) * 2019-10-11 2021-04-15 F. Hoffmann-La Roche Ag Drug dosage determination devices and methods
JP7763761B2 (ja) * 2020-01-08 2025-11-04 レスバーロジックス コーポレイション Betブロモドメイン阻害剤およびジペプチジルペプチダーゼ4阻害剤の組合せによる主要有害心血管イベント(mace)の治療方法および/または予防方法
CN111427913B (zh) * 2020-03-19 2023-07-25 上海太美星云数字科技有限公司 数据处理方法、设备、服务器、系统和计算机可读介质
EP4341963A1 (en) * 2021-05-19 2024-03-27 Charité - Universitätsmedizin Berlin Computer assisted method for the evaluation of cardiac metabolism
CN113362925B (zh) * 2021-06-29 2022-04-08 山东第一医科大学附属省立医院(山东省立医院) 一种自动良肢位控制方法及设备
CN114705871A (zh) * 2022-04-12 2022-07-05 复旦大学附属中山医院 8异前列腺素F2α在重度哮喘诊断中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
EP1675550A4 (en) * 2003-09-24 2007-10-10 Combinatorx Inc THERAPEUTIC DOSAGE DIAGRAMS FOR ADMINISTRATION OF MEDICINAL COMBINATIONS
MX2008001282A (es) * 2005-07-28 2008-03-24 Reliant Pharmaceuticals Inc Tratamiento con bloqueadores del canal del calcio de dihidropiridina y acidos grasos omega-3 y un producto de combinacion de los mismos.
US20080069878A1 (en) * 2006-08-31 2008-03-20 Gopi Venkatesh Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
US8999721B2 (en) * 2009-10-23 2015-04-07 Therabrake, Inc. Method and system to provide personalized pharmaceutical compositions and dosages
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
EP2680859B1 (en) * 2011-03-02 2022-04-27 Jerome Schentag Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
US20150352189A1 (en) * 2013-01-08 2015-12-10 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Similar Documents

Publication Publication Date Title
JP2017528431A5 (2)
ES2307463T3 (es) Forma de dosificación de combinación que contiene un agente reductor del colesterol, un inhibidor de la renina-angiotensina, y aspirina.
JP2015503593A5 (2)
AU2011261117B2 (en) Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
JP5619130B2 (ja) 中性ビニルポリマーおよび賦形剤を含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物
HRP20210686T1 (hr) Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom
JP2015522029A5 (2)
JP2019048843A5 (2)
JP2015503590A5 (2)
JP2017528516A5 (2)
US20110311631A1 (en) Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
RU2018120726A (ru) Комбинации с гемкабеном для лечения заболеваний сердечно-сосудистой системы
ES2623176T3 (es) Composición farmacéutica de memantina
JPWO2014050692A1 (ja) 糖尿病新規発症低減用組成物
Bader et al. Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro
JP2010539196A (ja) エタノールの影響に対して耐性を有する非オピオイド薬のpH依存性制御放出医薬組成物
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
JP2012503609A (ja) エタノールの影響に対する耐性を有するオピオイドではないpH依存の制御放出の医薬組成物
JP2017537168A5 (2)
KR20090114325A (ko) 약제학적 제제
RU2014127884A (ru) Способы лечения сердечно-сосудистого нарушения
JP2005538121A5 (ja) 多重遅延放出抗ウイルス物質産物、その使用法と製剤
ES2299072T3 (es) Procedimiento para la preparacion de formas medicamentosas con perfil de liberacion de principio activo estable.
Kim et al. Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial
MXPA04006780A (es) Formulaciones farmaceuticas de pravastatina y metodos para usarlas.